We understand how to position your discovery program for success while navigating through potential pitfalls, because we have years of experience in generation of therapeutic-quality antibodies from rodents, both wild-type and transgenic.

We work with companies large and small, ranging from companies operating virtually to established companies wanting to enhance their existing capabilities.

Our team of experts will become your team of experts, creating a tailored therapeutic discovery project based on the proven AlivaMab Mouse platform.


Larry Green, Ph.D.
Founder and CEO, co-inventor of the AlivaMab Mouse

Larry is CEO of AlivaMab Discovery Services and co-inventor of the AlivaMab Mouse. He also serves as CEO of Ablexis. Larry has a quarter century of experience in designing, creating and using transgenic mouse platforms for antibody drug discovery. Larry joined Aliva Biopharmaceuticals, Inc. in 2008 as CEO, where he optimized the blueprint for AlivaMab Mouse and procured a Series A financing, resulting in the founding of Ablexis, LLC in 2009. Prior to joining Aliva, he was a co-inventor of the XenoMouse® technology at Cell Genesys and was a scientific founder of the spin-out of Abgenix, where he served as designer and team leader for making improved versions of the XenoMouse® technology, director of antibody discovery operations, leader of the collaborations group, and the senior research representative on joint steering committees in alliances with Amgen, AstraZeneca and Pfizer, amongst other companies.


Larry is an inventor on several dozen patents covering immunoglobulin transgenic mice and therapeutic antibodies. He received his Ph.D. in Molecular and Cellular Biology from the University of Wisconsin-Madison and did postdoctoral research at the University of Colorado at Boulder and Stanford University.

John “Lippy” Lippincott, Ph.D.
Vice President of Research

Lippy is Vice President of Research at AlivaMab Discovery Services. He has nearly two decades of experience in the generation and characterization of antibodies from in vivo systems.


Prior to joining AlivaMab Discovery Services, Lippy established and led the hybridoma group at Pfizer’s San Diego site, where he was project leader for internal and co-development therapeutic discovery projects. At Igenica, he led the successful importation of a novel in vivo discovery platform and created a high-throughput system for hybridoma generation and screening, and led other processes required for identifying lead therapeutic candidates. Serving in the role of Vice President, Antibody Discovery at LakePharma, Lippy built and led the team responsible for providing antibody discovery services to clients. Lippy received his Ph.D. from Harvard University and did postdoctoral research at the Genomics Institute of the Novartis Research Foundation in San Diego.